MX2022012181A - Metodos y composiciones para tratar cancer. - Google Patents

Metodos y composiciones para tratar cancer.

Info

Publication number
MX2022012181A
MX2022012181A MX2022012181A MX2022012181A MX2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A MX 2022012181 A MX2022012181 A MX 2022012181A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating cancer
ppp2r2a
pkmyt1
Prior art date
Application number
MX2022012181A
Other languages
English (en)
Inventor
Stephen Harrison
Christine Taylor Brew
Michael David Winther
Sourabh Banerjee
Shawn Yost
Original Assignee
Engine Biosciences Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Engine Biosciences Pte Ltd filed Critical Engine Biosciences Pte Ltd
Publication of MX2022012181A publication Critical patent/MX2022012181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

En la presente se describen métodos y composiciones para tratar cáncer. Los métodos pueden comprender el uso de cantidades terapéuticamente efectivas de uno o más agentes para provocar una diferencia en la expresión o actividad de la proteína cinasa, tirosina/treonina 1 asociada a membrana (PKMYT1) en células de cáncer que son deficientes en la subunidad B alfa reguladora de proteína fosfatasa 2 (PPP2R2A).
MX2022012181A 2020-04-01 2021-03-31 Metodos y composiciones para tratar cancer. MX2022012181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063003736P 2020-04-01 2020-04-01
PCT/US2021/025230 WO2021202780A2 (en) 2020-04-01 2021-03-31 Methods and compositions for treating cancer

Publications (1)

Publication Number Publication Date
MX2022012181A true MX2022012181A (es) 2023-01-30

Family

ID=77927411

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012181A MX2022012181A (es) 2020-04-01 2021-03-31 Metodos y composiciones para tratar cancer.

Country Status (9)

Country Link
US (1) US20230149415A1 (es)
EP (1) EP4127722A4 (es)
JP (1) JP2023519931A (es)
KR (1) KR20230017167A (es)
CN (1) CN115769077A (es)
AU (1) AU2021249111A1 (es)
CA (1) CA3173799A1 (es)
MX (1) MX2022012181A (es)
WO (1) WO2021202780A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4388137A1 (en) * 2021-08-19 2024-06-26 Engine Biosciences Pte. Ltd. Compositions and methods for generating synthetic lethality in tumors
WO2023177356A2 (en) * 2022-03-18 2023-09-21 Engine Biosciences Pte. Ltd. Compounds and method for pkmyt1 inhibition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2660349C2 (ru) * 2012-11-28 2018-07-05 Мерк Шарп И Доум Корп. Композиции и способы для лечения злокачественной опухоли
JP2018518522A (ja) * 2015-06-23 2018-07-12 ケース ウエスタン リザーブ ユニバーシティ 癌を治療するための組成物及び方法

Also Published As

Publication number Publication date
US20230149415A1 (en) 2023-05-18
CA3173799A1 (en) 2021-10-07
EP4127722A2 (en) 2023-02-08
AU2021249111A1 (en) 2022-10-20
WO2021202780A2 (en) 2021-10-07
CN115769077A (zh) 2023-03-07
EP4127722A4 (en) 2024-05-01
KR20230017167A (ko) 2023-02-03
WO2021202780A3 (en) 2021-11-11
JP2023519931A (ja) 2023-05-15

Similar Documents

Publication Publication Date Title
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2022012181A (es) Metodos y composiciones para tratar cancer.
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
PH12020551180A1 (en) Methods and compositions for therapeutic protein delivery
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
MX2021001884A (es) Compuestos de pirazina y usos de los mismos.
MX2020009773A (es) Terapia de combinacion.
MX2021002998A (es) Compuestos de triazolo-pirimidina y usos de los mismos.
TW200510306A (en) Novel hydroxyindoles, their use as inhibitors of phosphodiesterase 4, and processes for preparing them
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
MX2022004937A (es) Inhibidores de las cinasas raf.
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
EA201891913A1 (ru) Улучшенные препараты клеток-предшественников взрослой печени
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
MX2022003570A (es) Composiciones de vesícula extracelular.
MX2017011633A (es) Uso de composiciones que contienen peptido inhibidor de mk2 para tratar cancer de pulmon de celulas no pequeñas con las mismas.
WO2018102687A3 (en) Combination therapy for treating cancer
CR20220355A (es) Compuestos activos frente a receptores nucleares
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112021021826A8 (pt) Uso de apremilaste e um inibidor da tirosina quinase 2 no tratamento de uma doença ou um transtorno responsivo à inibição da fosfodiesterase tipo 4
MX2023011326A (es) Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.